Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia

Blood

Volumn 122, Issue 16, 2013, Pages 2888-2892

  Zhang, Yi ^a   Owens, Kristina ^a   Hatem, Layla ^a   Glass, Carolyn H ^a   Karuppaiah, Kannan ^a   Camargo, Fernando ^b   Perkins, Archibald S ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE METHYLTRANSFERASE; HYBRID PROTEIN; MDS1 EVI1 FUSION PROTEIN; MIXED LINEAGE LEUKEMIA AF9 FUSION PROTEIN; UNCLASSIFIED DRUG; ISOPROTEIN; MDS1-EVI1 FUSION PROTEIN, HUMAN; MDS1-EVI1 FUSION PROTEIN, MOUSE; MIXED LINEAGE LEUKEMIA PROTEIN; MLL-AF9 FUSION PROTEIN, HUMAN; MLL-AF9 FUSION PROTEIN, MOUSE; ONCOPROTEIN;

ACUTE MYELOID LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; HEMATOCRIT; IN VITRO STUDY; LEUKEMOGENESIS; LEUKOCYTE COUNT; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; SPLEEN; THROMBOCYTE COUNT; TRANSCRIPTION INITIATION SITE; ACUTE BIPHENOTYPIC LEUKEMIA; ALLELE; ANIMAL; BONE MARROW; CELL LINEAGE; EXON; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHENOTYPE;

ALLELES; ANIMALS; BONE MARROW; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; EXONS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, BIPHENOTYPIC, ACUTE; MICE; MICE, KNOCKOUT; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PROTEIN ISOFORMS;

EID: 84891510354     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-453662     Document Type: Article

References (24)

1. Frankel LS, Ochs J, Shuster JJ, et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol. 1997;19(1):35-42.
2. Silverman LB, McLean TW, Gelber RD, et al. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer. 1997;80(12):2285-2295.
3. Reaman GH, Sposto R, Sensel MG, et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children’s Cancer Group. J Clin Oncol. 1999;17(2):445-455.
4. Bindels EMJ, Havermans M, Lugthart S, et al. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 2012;119(24):5838-5849.
5. Arai S, Yoshimi A, Shimabe M, et al. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood. 2011;117(23):6304-6314.
6. Chen W, Kumar AR, Hudson WA, et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell. 2008;13(5): 432-440.
7. Pinheiro I, Margueron R, Shukeir N, et al. Prdm3 and Prdm16 are H3K9me1 methyltransferases required for mammalian heterochromatin integrity. Cell. 2012;150(5):948-960.
8. Zhang Y, Stehling-Sun S, Lezon-Geyda K, et al. PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function. Blood. 2011;118(14):3853-3861.
9. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol. 2002;244(2):305-318.
10. Barabé F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science. 2007;316(5824): 600-604.
11. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol. 2004;22(12): 1567-1572.
12. Zhang Y, Sicot G, Cui X, et al. Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide. Biochemistry. 2011;50(48): 10431-10441.
13. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 1997;16(14): 4226-4237.
14. Dobson CL, Warren AJ, Pannell R, et al. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J. 1999;18(13): 3564-3574.
15. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104):818-822.
16. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006;10(4):257-268.
17. Krivtsov AV, Figueroa ME, Sinha AU, et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia. 2013;27(4): 852-860.
18. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature. 2008;455(7217): 1205-1209.
19. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65.
20. Grembecka J, He S, Shi A, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol. 2012;8(3): 277-284.
21. Jones B, Su H, Bhat A, et al. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet. 2008;4(9):e1000190.
22. Feng Y, Yang Y, Ortega MM, et al. Early mammalian erythropoiesis requires the Dot1L methyltransferase. Blood. 2010;116(22): 4483-4491.
23. Chen YX, Yan J, Keeshan K, et al. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci USA. 2006; 103(4):1018-1023.
24. Wu H, Min J, Lunin VV, et al. Structural biology of human H3K9 methyltransferases. PLoS ONE. 2010;5(1):e8570.